Skip to main content

Paggiarino Dario A.'s Form 4 filing

EyePoint, Inc. (EYPT) · filed Jan 25, 2024

Accession no.
0001562180-24-000637
Filed
Jan 25, 2024
Trade date
Jan 23-24, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 8 non-derivative transactions and 4 derivative transactions. Open-market sales total $409.8K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Paggiarino Dario A.CIK 0001574261Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 23, 2024Common StockMOption exerciseAcquired+3,096$13.13+$40,650.4839,601Direct
Jan 23, 2024Common StockMOption exerciseAcquired+2,039$12.90+$26,303.141,640Direct
Jan 23, 2024Common StockSSaleDisposed−2,039$25.00−$50,97539,601Direct
Jan 23, 2024Common StockSSaleDisposed−3,096$25.00−$77,40036,505Direct
Jan 24, 2024Common StockMOption exerciseAcquired+5,651$12.90+$72,897.942,156Direct
Jan 24, 2024Common StockMOption exerciseAcquired+5,600$13.13+$73,52847,756Direct
Jan 24, 2024Common StockSSaleDisposed−5,600$25.01F1−$140,05642,156Direct
Jan 24, 2024Common StockSSaleDisposed−5,651$25.02F1−$141,388.0236,505Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 23, 2024Common StockMOption exerciseDisposed−3,096$0.00$057,204Direct
Jan 23, 2024Common StockMOption exerciseDisposed−2,039$0.00$022,586Direct
Jan 24, 2024Common StockMOption exerciseDisposed−5,600$0.00$051,604Direct
Jan 24, 2024Common StockMOption exerciseDisposed−5,651$0.00$016,935Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.14. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)